Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury

A proton pump inhibitor, tegaserod technology, applied in the direction of drug combination, active ingredients of heterocyclic compounds, medical preparations containing active ingredients, etc., can solve the problems of high gastrointestinal toxic side effects, serious costs and other problems

Inactive Publication Date: 2009-06-24
NOVARTIS AG
View PDF18 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, there is substantial evidence that NSAIDs have frequent, severe and costly gastrointestinal toxic side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury
  • Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury
  • Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury

Examples

Experimental program
Comparison scheme
Effect test

other Embodiment approach

[0031] In other embodiments, compositions of the invention are used to treat gastric damage in a subject. In certain embodiments, gastric injury includes inflammatory bowel disease (IBD) and functional bowel disorder (FBD), including dyspepsia, Crohn's disease, ileitis, ischemic bowel disease, and ulcerative colitis, Dyspepsia, and gastroesophageal reflux for FBD and various forms of visceral pain. In certain embodiments, the gastric injury is caused by the subject's use of an NSAID. In a specific embodiment, the gastric damage is mucosal damage, gastric muscle dysfunction, gastritis, gastric erosion, ulcer or gastric damage.

[0032] In certain embodiments, the invention provides pharmaceutical compositions of any of the compositions of the invention. In a related embodiment, the invention provides a pharmaceutical composition of any of the compositions of the invention with a pharmaceutically acceptable carrier or excipient for any of these compositions. In certain embodi...

other Embodiment approach

[0034] In other embodiments, the present invention provides the use of any of the compositions of the present invention in the manufacture of a medicament for treating gastric damage in a subject. In other embodiments, the invention provides methods of preparing a medicament for treating a subject comprising formulating any of the compositions of the invention.

[0035] In some embodiments, a method of treating gastric damage in a subject comprises administering an effective amount of tegaserod to the subject in need thereof. In other embodiments, a method of treating gastric injury in a subject comprises administering to the subject a first dose of tegaserod and at least one-half the dose of a PPI, such as omeprazole. The treatment of gastric damage is an additive or synergistic effect compared to the effect in the presence of tegaserod or PPI administered alone. In some embodiments, administration of tegaserod and a PPI results in a synergistic increase in the treatment of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to methods for treating, preventing and / or managing gastric injury, e.g., NSAID-induced gastric injury in a subject including administering to the subject tegaserod, alone or in combination with a proton pump inhibitor. Also provided are compositions and kits for use in methods of the invention.

Description

[0001] related application [0002] This application claims the benefit of US Provisional Application No. 60 / 813,852, filed June 15, 2006. The contents of any patents, patent applications and references cited throughout this specification are hereby incorporated by reference in their entirety. field of invention [0003] The present invention relates to a method of preventing gastric damage such as mucosal damage and gastric muscle dysfunction by administering tegaserod alone or in combination with a proton pump inhibitor to a subject in need thereof. Background of the invention [0004] Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly prescribed drugs for the treatment of pain associated with a variety of musculoskeletal and inflammatory conditions. In the United States, approximately 100 million prescriptions are filled annually to effectively relieve pain and treat inflammatory diseases. Commonly used NSAIDs include sulindac, naproxen, indomethacin, m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/19A61K31/196A61K31/341A61K31/40A61K31/4045A61K31/405A61K31/407A61K31/415A61K31/42A61K31/4402A61K31/4439A61K31/5415A61K31/60A61K45/00A61P1/00
CPCA61K45/06A61K31/19A61K31/4402A61K31/60A61K31/405A61K31/407A61K31/415A61K31/42A61K31/4439A61K31/4045A61K31/5415A61K31/341A61K31/196A61K31/40A61P1/00A61P1/02A61P1/04A61P11/00A61P11/06A61P15/00A61P17/00A61P17/02A61P19/08A61P21/00A61P21/04A61P25/04A61P25/06A61P27/02A61P29/00A61P7/06A61P9/00A61K2300/00A61K31/404
Inventor D·L·伊尔内斯特
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com